Data supplement to Baxter et al. Reducing excess mortality due to chronic disease in people with severe mental illness: meta-review of health interventions. Br J Psychiatry doi: 10.1192/bjp.bp.115.163170

Search method

For this review we searched four relevant electronic databases: the Cochrane database of systematic reviews; the Database of abstracts of reviews of effects (DARE); Campbell database of systematic reviews; and Database of promoting health effectiveness reviews (DoPHER). Both qualitative meta-analyses and narrative reviews of the literature were accepted providing they reported effect sizes of included studies and the characteristics of the intervention group the versus control group.

Information sources:

Cochrane database of systematic reviews (Cochrane reviews) (1996-; updated quarterly):

A source of up-to-date information on the effects of interventions in health care, designed to provide information and evidence to support decisions taken in health care and to inform those receiving care.

<u>Database of abstracts of reviews of effects (DARE)</u> through the University of York Centre for Reviews and Dissemination (CRD) Assessed reviews (<u>www.york.ac.uk/inst/crd</u>) (1994-; updated monthly):

Reviews of research evidence which locate, appraise and synthesise evidence from scientific studies in order to provide informative empirical answers to scientific research questions. The reviews are identified by regular searching of bibliographic databases, hand searching of key major medical journals, and by scanning grey literature. These searches are conducted by the information staff of the NHS Centre for Reviews and Dissemination. The following databases are currently searched: Current Contents Clinical Medicine (weekly), MEDLINE (monthly), CINAHL (monthly), ERIC (annually), Biosis (annually), Allied and Alternative Medicine (annually), PsycINFO (annually)

Campbell database of systematic reviews(http://www.campbellcollaboration.org/)

<u>Database of promoting health effectiveness reviews (DoPHER):</u>

(http://eppi.ioe.ac.uk/webdatabases/Intro.aspx?ID=2). Provides focussed coverage of systematic and non-systematic reviews of effectiveness in health promotion and public health worldwide.

CINAHL (including MEDLINE) (1982-):

Search strings:

<u>Cochrane Library:</u> (mental disorder*:kw or "schizophrenia":kw or bipolar*:kw or depress*:kw) AND (survival*:ti,ab,kw or mortality*:ti,ab,kw or death rate*:ti,ab,kw) AND (*therapy:kw or "intervention studies":kw or *health care*:kw), in Cochrane Reviews (Reviews only) (Word variations have been searched)

<u>DoPHER:</u> (Freetext: 'mental disorder' or schizophrenia or depression or bipolar) AND (Freetext: mortality or survival or deaths) AND (Type of study: meta-analysis or review or systematic review)

<u>CINAHL (including Medline):</u> (MW mental disorders OR MW schizophrenia OR MW schizoaffective disorders OR MW bipolar disorder OR MW depression) AND (MW interventions OR MW treatment OR MW case management OR MW therapies OR MW therapy OR MW health care) AND (AB mortality OR AB death* OR AB survival). Limiters - Exclude Pre-CINAHL; Human; Publication Type: Meta Analysis, Meta Synthesis, Review, Systematic Review. Search modes - Boolean/Phrase

Table DS1	Summary of review pap	ers reporting the effect	of interventions on p	hysical heal	th in pe	ople with sev	ere mental illness	
	Study group	Intervention(s)	Outcomes*	Review type	Study types		Findings relevant to physical health outcomes	AMSTA R score (out of 11)
Mental health	interventions							
Jones <i>et al</i> (2012) (22)	People with current diagnosis of schizophrenia	СВТ	Adverse effect/events including mortality, relapses and hospitalisation	Systematic review & meta- analysis	20	RCTs	Death (2 RCTs) RR=0.57 (95%CI 0.12-2.60)	10
Von Ruden <i>et</i> al (2008) (21)	People prescribed or taking anti-depressants (not necessarily with SMI)	Antidepressants	Cardiovascular events (including mortality)	Systematic review	13	Controlled clinical trials, cohort or case-control studies	Study heterogeneity prevented pooling of summary measures. Includes at least 2 studies where patients had pre-existing CVD (ie depression was subsequent to cardiac disease), 6-7 where no diagnosis SMI was required	3
Weinmann, Read & Aderhold (2009) (20)	Adults with schizophrenia, schizoaffective disorder or other severe mental illness such as bipolar disorder prescribed antipsychotics	Antipsychotic medications	All cause and cause- specific mortality	Systematic review	12	Controlled clinical trials, cohort or case-control studies	Study heterogeneity prevented pooling of summary measures. Antipsychotic dosage and mortality: 3 out of 5 reported a dose effect. Antipsychotic polypharmacy and mortality: 2 out of 4 found an increased risk. No evidence was found for increased	8

mortality in relation to 1st versus 2nd generation antipsychotics.

Integrative con	nmunity care							
Dieterich <i>et al</i>	Adults with SMI (defined	Intensive case	Mortality	Systematic	38	RCTs	With standard care as the	8
(2010) (30)	as schizophrenia,	management described a	as	review &			comparator: Any death (9 RCTs)	
	schizophrenia-like	a package of care based		meta-			RR=0.84 (95%Cl 0.48-1.47); Death	
	disorders, bipolar	on: a) the Assertive		analysis			by suicide (9 RCTs) RR=0.68 (95%CI	
	disorder, depression with	Community treatment					0.31 -1.51)	
	psychotic features or/and	model; b) Assertive						
	personality disorder; and	outreach model (i.e.						
	not acutely ill)	multidisciplinary team-						
		based approach); or c)						
		Case management mode	l;					
		with a caseload up to and	d					
		including 20 people.						
Malone <i>et al</i>	People presenting to, or	Community mental healt	h Mortality	Systematic	3	RCTs	Any death (3 RCTs) RR=0.47 (95%CI	10
(2007) (29)	being referred to, adult	team (CMHT) treatment,		review &			0.2-1.3); Death by	
	psychiatric	defined as management		meta-			suicide/suspicious circumstances (2	
	services with SMI	of care from a multi-		analysis			RCTs) RR=0.49 (95%CI 0.1-2.2);	
		disciplinary, community-					Death due to physical health (3	
		based team					RCTs) RR=0.51 (95%CI 0.1-2.0)	

Alvarez-	Patients with	Non-pharmacological	Mean change in body	Systematic	10		WMD = -2.56KG (95%CI -3.20 to -	10
Jimenez (2008)	schizophrenia taking	interventions	weight gain and BMI	review			1.92kg, p<0.001)	
(42)	antipsychotics							
Cabassa et al	SMI (including but not	Behavioral techniques to	Weight loss, systolic	Systematic	23	RCTs, quasi-	Amongst single-group studies,	7
(2010) (41)	limited to schizophrenia,	improve dietary habits	blood pressure, diastolic	review		experimental	mean weight loss of 4.3±5.6	
	bipolar and	and increase physical	blood pressure, HbA1C			and single	pounds. Amongst the quasi-	
	schizoaffective disorder)	activity	levels, triglycerides and			group studies	experimental studies, mean weight	
			central adiposity levels				loss of 5.9±6 pounds. Among the	
							RCTs mean weight loss of 3.7±2.3	
Caemmerer,	Patients using	Non-pharmacological	Weight loss or	Systematic	17	RCTs	Non-pharmacological interventions	6
Correll &	antipsychotic medication	interventions	maintenance, insulin	review &			resulted in a significant weight	
Maayan (2012)			and glucose levels,	meta-			change of -3.12kg (95%CI -4.03 to	
(37)			blood lipids and systolic	analysis			-2.21; 14 studies) and a significant	
			blood pressure				change of BMI of -0.94kg/m ²	
							(95%CI -1.45 to -0.43; 16 studies)	
							compared to control. There was	
							significant improvement in insulin	
							levels (3 RCTs) (WMD= -4.93	
							uIU/mL, p<0.001) and fasting	
							glucose levels (6 RCTs) (WMD= -	
							5.79 mg/dL, p<0.001).	
Faulkner <i>et al</i>	Schizophrenia or	Pharmacological and	Weight gain	Systematic	23	RCTs	No summary measures reported.	8
(2007) (43)	schizophrenia-like	behavioural strategies for		review				
	illnesses	reducing weight gain						

Galletly &	SMI (disorders with	Lifestyle interventions	Weight-loss/obesity	Systematic	16	Not reported	Significant (p<0.05) within-subject	4
Murray (2009)	psychotic symptoms)	targeting weight loss	management	review			results were reported in 6 of the 11	
(38)							weight loss studies	
Gierisch et al	Adults with SMI	Pharmacological, patient	All-cause mortality, CVD	Systematic	35	RCTs	Mean weight loss associated with	10
(2013) (32)	(schizophrenia or	focused behavioural	risk factors (glucose	review &			behavioural interventions was	
	schizoaffective disorder,	strategies for health	level, lipid level), weight	meta-			about -3.1 kg (95%CI -4.2-2.1); with	
	bipolar, or major	behaviours and peer and	control	analysis			anticonvulsants about -5.1kg	
	depression with psychotic	family support					(95%CI -9.5-0.7); and metformin	
	features)	interventions					about -4.1 (95%CI 6.8 to -1.7). In 2	
							studies metformin was also	
							associated with small	
							improvements in HbA1c. Six of 15	
							trials evaluating blood lipid levels	
							found significant improvement	
							with treatment (in each case	
							pharmacological).	
Hunt et al	People with SMI (for	Psychosocial interventions	All-cause mortality	Systematic	32	RCTs	Long-term integrated care was not	10
(2013) (33)	example,	for substance misuse		review &			associated with change in risk of	
	schizophrenia, bipolar	categorised into a)		meta-			death at 3 years (2 RCTs) RR=1.18	
	disorder and psychosis)	Integrated models of care,		analysis			(95%CI 0.39-3.57).	
	and concurrent	b) individual approaches						
	problem of substance	(CBT; Motivational					Motivational interviewing + CBT	
	misuse.	interviewing; Contingency					compared to usual treatment	
		management) and c)					showed no benefit for reducing	
		Group approaches (skills					deaths after an average of 12	

		training).					months (3 RCTs) RR=0.72 (95%CI	
							0.22-2.41).	
Tosh et al	Adults with SMI (defined	General health advice	Health measures	Systematic	7	RCTs	Death (2 RCTs) RR=0.98 (95%CI	11
(2014) (31)	as schizophrenia,	(defined as preventative	(metabolic criteria and	review &			0.27-3.56); Presence of metabolic	
	schizophrenia-like	information or counsel	syndrome, heart score	meta-			syndrome (1 RCT) RR=1.25 (95%CI	
	disorders, bipolar	where it is left to the	and physical work	analysis			0.35-4.49)	
	disorder, or serious	recipient to make the final	capacity) and adverse					
	affective disorders)	decision)	events (eg. weight gain,					
			cardiac event, mortality)					
van Hessalt et	Adults with SMI (included	Behavioural therapies	Weight, CVD risk factors	Systematic	22	RCTs	No summary measures reported.	3
al (2013) (40)	were schizophrenia and	including CBT, structured	(cholesterol,	review				
	psychosis, PTSD or mood	educational and skill-	Framingham risk score),					
	disorders, and DSM-IV	development programs,	exercise, smoking,					
	diagnosis, anxiety	peer-led support groups,	general health scores,					
	disorder or a combination	and improved access to	diet					
	of these)	facilities.						
Verhaeghe et	SMI (not defined)	Lifestyle interventions	BMI; change in body	Systematic	14	Not reported	Weighted average weight change	7
al (2011) (39)		targeting physical activity	weight; general health	review			based on sample size in the	
		and eating habits					intervention groups was -1.96 ±	
							1.84 kg (-1.74%) versus +1.77 ±	
							2.12 kg (+2.28%) in the control	
							groups.	
							Weighted average BMI change	
							based on sample size in the	
							intervention groups was -0.87 ±	

 $0.69 \text{ kg/m2 versus } + 0.64 \pm 0.96 \text{ kg/m2 in the control groups.}$

Screening and monitoring of health parameters										
Tosh <i>et al</i>	SMI (schizophrenia,	Physical health care	Physical health, adverse	Systematic	0	RCTs	No summary measures reported.	4		
(2014) (16)	schizophrenia-like	monitoring	effects of treatment	review						
	disorders, bipolar disord	der								
	or serious affective									
	disorders)									

^{*}Only physiological outcomes are reported here. Reviews may have captured and summarised other outcomes (eg quality of life, psychiatric symptoms, health services use) in addition to those pertinent to this meta-review.

SMI: severe mental illness; CVD: cardiovascular disease; CBT: cognitive behavioural therapy; RCTs: randomised controlled trials; SSRIs: selective serotonin reuptake inhibitors; BMI: Body mass index.

Table DS2 AMSTAR measurement tool to assess the methodological quality of systematic reviews

		1		J the m	ı		•					
	1. Was an 'a priori' design provided?	2. Was there duplicate study selection and data extraction?	3. Was a comprehensive literature search performed?	4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?	5. Was a list of studies (included and excluded) provided?	 Were the characteristics of the included studies provided? 	7. Was the scientific quality of the included studies assessed and documented?	8. Was the scientific quality of the included studies used appropriately in formulating conclusions?	9. Were the methods used to combine the findings of studies appropriate?	10. Was the likelihood of publication bias assessed?	11. Was the conflict of interest included?	Total Score (Out of 11)
Mental health interventions												•
Jones <i>et al</i> (2012) [22]	②	?	②	②	②	②	②	②	②	②	②	10
Von Ruden <i>et al</i> (2008) [19]	②	×	×	×	*		×	×	×	×	②	3
Weinmann, Read & Aderhold	②	©	⊘	×	**	②	⊘	⊘	©	×	②	8
(2009) [18]										•••		
Collaborative care interventions	<u> </u> 											
Dieterich <i>et al</i> (2010) [30]	⊘	×	②	×	*	②	②	②	②		②	8
Malone <i>et al</i> (2007) [29]	②			②						?	②	10
Intervention for lifestyle factors											l	
Alvarez- Jimenez (2008) [39]	②	②	②	②	②	②	②	②	②		×	10
Cabassa <i>et al</i> (2010) [38]	②	©	②	②	× *	②		②	×	×	×	7
Caemmerer, Correll & Maayan	②	×		×	**	②	×	×	②			6
(2012) [34]												
Faulkner <i>et al</i> (2007) [40]	②	×	②	②	**	②	②	②	②	?	②	8
Galletly & Murray (2009) [35]	②	×	②	×	**	•	×	×	×	×	②	4
Gierisch et al (2013) [32]	②		②	②	*		②		②	Ø		10
Hunt et al (2013) [33]	②	×	②	②	②	②	②		②	②		10
Tosh et al (2014) ² [31]	②	②		②			②		②		②	11
van Hessalt <i>et al</i> (2013) [37]	②		×	×	**		×	×	×	×	×	3
Verhaeghe <i>et al</i> (2011) [36]	②	×	②	×	②		②		×	×		7
Screening and monitoring of hea	alth par	amete	rs	1	ı							

NA
Not
Appli
cable
Can't
Answ

er

Tosh <i>et al</i> (2014)¹ [16]	②	NA	②	?	②	NA	NA	NA	NA	NA	②	4
--------------------------------	----------	----	----------	---	----------	----	----	----	----	----	----------	---

Item 5: \mathbf{x}^* Reviews provided references for the included studies, but not for the excluded studies.

Item 6: Study characteristics are reported throughout the text sporadically and therefore difficult to extrapolate